Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/46790
Type
ArticleCopyright
Open access
Sustainable Development Goals
03 Saúde e Bem-EstarCollections
- IOC - Artigos de Periódicos [12973]
Metadata
Show full item record
OXIDATIVE IMBALANCE AS A CRUCIAL FACTOR IN INFLAMMATORY LUNG DISEASES: COULD ANTIOXIDANT TREATMENT CONSTITUTE A NEW THERAPEUTIC STRATEGY?
Fator Crucial
Doenças inflamatórias de Pulmão
Tratamento antioxidante
Nova Estratégica terapêutica ?
Crucial Factor
nflammatory Lung Diseases
Antioxidant Treatment
New Therapeutic Strategy?
Affilliation
University of Lyon. VetAgro Sup. APCSe, Marcy l'Étoile, France.
Universidade federal de Alagoas. Laboratório de Biologia Celular. Maceió, AL, Brasil.
NuMeCan Institute (Nutrition, Metabolism and Cancer), INSERM, INRAE, CHU Rennes, Univ Rennes, Rennes, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de IInflamação. Rio de Janeiro, RJ, Brasil.
Universidade federal de Alagoas. Laboratório de Biologia Celular. Maceió, AL, Brasil.
NuMeCan Institute (Nutrition, Metabolism and Cancer), INSERM, INRAE, CHU Rennes, Univ Rennes, Rennes, France.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de IInflamação. Rio de Janeiro, RJ, Brasil.
Abstract
Inflammatory lung disease results in a high global burden of death and disability. There are no effective treatments for the most
severe forms of many inflammatory lung diseases, such as chronic obstructive pulmonary disease, emphysema, corticosteroid resistant asthma, and coronavirus disease 2019; hence, new treatment options are required. Here, we review the role of oxidative
imbalance in the development of difficult-to-treat inflammatory lung diseases. The inflammation-induced overproduction of
reactive oxygen species (ROS) means that endogenous antioxidants may not be sufficient to prevent oxidative damage, resulting
in an oxidative imbalance in the lung. In turn, intracellular signaling events trigger the production of proinflammatory
mediators that perpetuate and aggravate the inflammatory response and may lead to tissue damage. The production of high
levels of ROS in inflammatory lung diseases can induce the phosphorylation of mitogen-activated protein kinases, the
inactivation of phosphoinositide 3-kinase (PI3K) signaling and histone deacetylase 2, a decrease in glucocorticoid binding to its
receptor, and thus resistance to glucocorticoid treatment. Hence, antioxidant treatment might be a therapeutic option for
inflammatory lung diseases. Preclinical studies have shown that antioxidants (alone or combined with anti-inflammatory drugs)
are effective in the treatment of inflammatory lung diseases, although the clinical evidence of efficacy is weaker. Despite the high
level of evidence for the efficacy of antioxidants in the treatment of inflammatory lung diseases, the discovery and clinical
investigation of safer, more efficacious compounds are now a priority.
Keywords in Portuguese
Desequilíbrio OxidativoFator Crucial
Doenças inflamatórias de Pulmão
Tratamento antioxidante
Nova Estratégica terapêutica ?
Keywords
Oxidative ImbalanceCrucial Factor
nflammatory Lung Diseases
Antioxidant Treatment
New Therapeutic Strategy?
Share